News & Publications

Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update

Gate Neurosciences today announced the results of research, published in the International Journal of Neuropsychopharmacology, supporting the mechanism of action and clinical foundation of Zelquistinel – the company’s lead oral program in Phase 2 development – as a rapid-acting, long-lasting and safe antidepressant.

Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Zelquistinel is an Orally Bioavailable Novel NMDAR Modulator that Exhibits Rapid & Sustained Antidepressant Effects

Highlights our lead program, Zelquistinel, and it’s unique mechanism of positive NMDA receptor modulation and that enhances long-term potentiation and synaptic function, resulting in rapid and sustained antidepressant activity with an improved safety profile versus NMDA antagonists.

Repeated Administration of Rapastinel Produces Prolonged Rescue of Memory Deficits in Mice Treated with NMDAR Antagonists

Highlights the differentiated mechanism and effects on cognition of our class of NMDAR modulators, compared to NMDAR antagonists. Gate’s unique NMDAR modulator mechanism reverses and rescues brain deficits caused by NMDAR antagonists such as PCP and ketamine.

Positive Modulation of NMDA Receptors by AGN-241751 exerts rapid antidepressant effects via Excitatory Neurons

Highlights our lead program, Zelquistinel, and the novel NMDAR mechanism by which our compounds act on excitatory neurons in the mPFC, but not inhibitory neurons, to drive antidepressant effects

Cell-Type Specific Modulation of NMDA Receptors Triggers Antidepressant Actions

Highlights and differentiates the mechanistic pathways by which Gate’s NMDAR positive modulators, and NMDA antagonists (ie ketamine), can both exert rapid antidepressant effects. Gate’s NMDA modulators directly enhance receptor function on principal glutamatergic neurons in the mPFC, whereas antagonists block NMDA on GABA interneurons causing a glutamate efflux (and dissociative side effects) and indirect activation of excitatory synapse.

Rapastinel Alleviates the Neurotoxic Effects Induced by NMDA Receptor Blockade

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

NMDAR Modulators as Rapid Antidepressants, Converging and Distinct Signaling Mechanisms

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine

Highlights Gate’s NMDAR modulators lower propensity than ketamine to induce CNS-related adverse side effects and sleep disturbances.

Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms

Highlights how Gate’s NMDAR modulators exert rapid (within hours) and long-lasting (7-10 days) of antidepressants but without has no ketamine-like side effect such as cognitive impairment and psychotomimetic symptoms.

1 2